Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8019-8027

  Celetti, Angela ^a   Testa, Domenico ^a   Staibano, Stefania ^a   Merolla, Francesco ^a   Guarino, Valentina ^a   Castellone, Maria Domenica ^a   Iovine, Renata ^a   Mansueto, Gelsomina ^a   Somma, Pasquale ^a   De Rosa, Gaetano ^a   Galli, Vieri ^a   Melillo, Rosa Marina ^a   Santoro, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKINE; HERMES ANTIGEN; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OSTEOPONTIN;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CELL PROLIFERATION; CELL SURFACE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; ENZYME HISTOCHEMISTRY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ITALY; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BUTADIENES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; NITRILES; OSTEOPONTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 28144446043     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0641     Document Type: Article

References (45)

1. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311-6.
2. Licitra L, Bernier J, Grandi C, et al. Cancer of the larynx. Crit Rev Oncol Hematol 2003;I47:65-80.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-94.
4. Hoffman HT, Karnell LH, Funk GF, Robinson RA, Menck HR. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998;124:951-62.
5. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, et al. Multiple head and neck tumours frequently originate from a single preneoplastic lesion. Am J Pathol 2002; 161:1051-60.
6. Shin DM, Lee JS, Lippman SM, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-29.
7. Bellacosa A, Almadori G, Cavallo S, et al. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 1996;2:175-80.
8. Pignataro L, Pruneri G, Carboni N, et al. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol 1998;9:3069-77.
9. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
10. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000;18:2046-52.
11. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol 1999;17:3150-9.
12. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-4.
13. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin on autoimmune demyelinating disease. Science 2001; 294:1731-5.
14. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.
15. 1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999;59:219-26.
16. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-81.
17. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001;1552:61-85.
18. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
19. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-21.
20. Schorge JO, Drake RD, Lee H, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004;10:3474-8.
21. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
22. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-23.
23. Hermanek P, Sobin LH, Larynx. In: Hermanek P, Sobin LH, editors. TNM classification of malignant tumors. Berlin (Germany): Springer-Verlag; 1987. p. 25-8.
24. Rosai J, Carcangiu ML, DeLellis RA. Atlas of tumor pathology-tumors of the larynx, 3rd series. Washington: Armed Force Institute of Pathology; 1992.
25. Kawamata H, Nakashiro K. Uchida D, Harada K, Yoshida H, Sato M. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 1997;70:120-7.
26. Gioanni J, Fischel JL, Lambert JC, et al. Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol 1988;24:1445-55.
27. Moore AE, Sabachewsky L, Toolan HW. Culture characteristics of four permanent lines of human cancer cells. Cancer Res 1955;15:598-602.
28. Eagle H. Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc Soc Exp Biol Med 1955;89:362-4.
29. Weiss JM, Renkl AC, Maier CS, et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 2001;194:1219-29.
30. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9:31-2.
31. Senger DR, Wirth DF, Hytnes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979;16:885-93.
32. Medico E, Gentile A, Lo Celso C, et al. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 2001;61:5861-8.
33. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000;83:156-63.
34. Chackalaparampil I, Peri A, Nemir M, et al. Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein. Oncogene 1996;12:1457-67.
35. Morimoto I, Sasaki Y, Ishida S, Imai K, Tokino T Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer 2002; 3:270-8.
36. Liu M, Lawson G, Delos M, et al. Prognostic value of cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in primary squamous cell carcinoma of the larynx and hypopharynx. Eur Arch Otorhinolaryngol 2003;260:28-34.
37. Bourguignon LY, Gilad E, Rothman K, Peyollier K. Hyaluronan-CD44 interaction with IQGAPI promotes Cdc42 and ERK signaling leading to actin binding, Elk-1/estrogen receptor transcriptional activation and ovarian cancer progression. J Biol Chem 2005;280:11961-72.
38. Teramoto H, Castellone MD, Malek RL, et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 2005;24:489-501.
39. Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated CD44 interaction with Rho-GEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 2003;278:29420-34.
40. Murphy JF, Lennon F, Steele C, Kelleher D, Fitzgerald D, Long A. Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and cell proliferation in human vascular endothelial cells. FASEB J 2005;19:446-8.
41. Zhang Y, Thant AA, Machida K, et al. Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res 2002;62:3962-5.
42. Gao C, Quo H, Downey L, Marroquin C, Wei J, Kuo PC. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 2003; 24:1871-8.
43. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002;16:3074-86.
44. Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 2005;280:8875-83.
45. Tuck AB, Hota C, Wilson SM, Chambers AF. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003;22:1198-205.